Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04339621 · ClinicalTrials.gov registry record
AIH Risk Stratification With Multiparametric MRI
A clinical trial, sponsored by Perspectum.
- Terminated
- Registry status
- 11
- Enrollment target
NCT04339621 is a clinical trial that was terminated before completion, run by Perspectum. The registered enrollment target is 11 participants.
The verdict
NCT04339621 was terminated before completion, sponsored by Perspectum.
- TERMINATED
- Registry status
- 11 participants
- Enrollment target
Study Summary
The primary aim of this study is to investigate whether the baseline cT1 can predict those whose condition relapses following treatment withdrawal. The secondary aim is to investigate correlation of cT1 with histology to explore utility as a monitoring tool. A total of 97 patients with AIH will be recruited and divided into 2 arms. 20 of which will be treatment naive and the other 77 will have been on treatment for the past 18-24 months and will be coming in for therapy cessation review.
Interventions
- DEVICE LiverMultiscan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2020-10-20 |
| Est. Completion | 2023-04-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04339621
The ClinicalTrials.gov registry entry for NCT04339621 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Perspectum, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LiverMultiscan is the first listed.
NCT04339621 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04339621 about?
NCT04339621 is a clinical study titled "AIH Risk Stratification With Multiparametric MRI". The primary aim of this study is to investigate whether the baseline cT1 can predict those whose condition relapses following treatment withdrawal. The secondary aim is to investigate correlation of cT1 with histology to explore utility as a monitoring tool. A total of 97 patients with AIH will be...
What is the current status of trial NCT04339621?
This trial is currently terminated. The enrollment target is 11 participants. The study started on 2020-10-20. Estimated completion is 2023-04-15.
What interventions are being tested in trial NCT04339621?
The interventions under investigation include: LiverMultiscan (DEVICE).
Who is sponsoring clinical trial NCT04339621?
This trial is sponsored by Perspectum, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.